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Abstract
Although major depressive disorder imposes a serious public health burden and affects nearly one in six individuals
in developed countries over their lifetimes, there is still no consensus on its pathophysiology. Inflammation and
cytokines have emerged as a promising new avenue in depression research, and, in particular, macrophage
migration inhibitory factor (MIF) has been shown to be significant in depression physiology. In this review we
summarize current research on MIF and depression. We highlight the arguments for MIF as a pro- and
antidepressant species and discuss the potential implications for therapeutics.
Keywords: MIF, Depression, Neuroinflammation, Neurogenesis, Antidepressant, Biomarker

Introduction
Major depressive disorder (MDD) is a clinical syndrome
defined by chronic disturbances in emotion and ideation
that are accompanied by somatic or neurovegetative symptoms [1]. The disease has a worldwide lifetime prevalence
of 12%, with the prevalence in developed countries (USA
and Europe) as high as 18% [2]; this figure is increasing
over time [3]. Additionally, depressive mood is often comorbid with other psychiatric conditions such as anxiety
and eating disorders, as well as with chronic medical conditions such as cancer, cardiovascular disease, neurological
disorders, and chronic inflammatory diseases [4]; this is
often called ‘secondary depression’ [5]. Comorbid depression significantly worsens outcomes in coronary heart disease, diabetes mellitus, and stroke [6,7]. Depression can
also cause cognitive symptoms [8] that can produce severe
psychosocial deficits [9]. Despite these considerations, treatment for depression has not changed significantly in recent
years. Current treatments do not adequately address cognitive deficits in depression [10], and there remain few solutions for treatment-resistant depression, which affects
almost half of the patient population [11].
One of the reasons for the slow progress in this area is
the lack of a unified theory of the pathobiology of depression. Several hypotheses are currently supported by research. One of the oldest is the monoamine theory, which
asserts that depression is caused by a depletion of
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monoamines (such as serotonin or norepinephrine) in the
brain [12]. Selective serotonin reuptake inhibitors (SSRIs)
operate on this premise, and they are currently among the
first-line treatments for major depression [13]. However,
this theory fails to explain the delay in remission during
treatment with SSRIs, or why depletion of monoamines
does not reproduce depressive symptoms in healthy controls. As a result, a neurotrophic theory of depression has
emerged: atrophic changes are found in the postmortem
brains of MDD patients, and increases in neurogenesis or
neuroplastic factors have antidepressant effects [12]. Any
unified theory of depression would doubtless need to incorporate aspects of both of these hypotheses.
A large body of evidence has also pointed to an inflammatory etiology in depression [14]. Depressed mood
develops in nearly a third of patients treated with recombinant interferon alpha, and is more prevalent in patients
with chronic inflammatory diseases [15,16]. Systemic inflammation produces sickness behavior that resembles depression in both patients and rodent models [17]. One of
the challenges of this hypothesis is explaining how peripheral cytokines can cross the blood brain barrier and affect
the central nervous system to induce depression. One proposed explanation centers on the cytokine-activated enzyme indoleamine 2,3-dioxygenase, which has been shown
to induce depression-like behavior. It degrades neural tryptophan into 3-hydroxykyurenin and quinolinic acid; in
addition to being neurotoxic, these metabolites also drain
local stores of tryptophan, which is a prerequisite in the
synthesis of serotonin [18].

© 2014 Bloom and Al-Abed; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.

Bloom and Al-Abed Journal of Neuroinflammation 2014, 11:11
http://www.jneuroinflammation.com/content/11/1/11

Macrophage migration inhibitory factor

With mounting evidence for a role for cytokines in depression, macrophage migration inhibitory factor (MIF)
has emerged as a strong candidate for a pathophysiological role. MIF is one of the first cytokines to be investigated, originally identified by its ability to prevent
random migration of macrophages. It is released from
intracellular pools by T- and B-lymphocytes, monocytes,
macrophages, dendritic cells, neutrophils, eosinophils,
mast cells, and basophils. It is also widely distributed in
tissues [19]. Its release is triggered when cells are exposed to microbial products, pro-inflammatory cytokines, or specific antigens. Upon release, it acts in an
autocrine and paracrine fashion to induce production of
pro-inflammatory cytokines [20]. It also opposes the
anti-inflammatory activity of glucocorticoids [21], which
will be discussed later. Finally, it has been shown to have
a role in cellular responses to DNA damage and cell
cycle regulation [22]. MIF has been implicated in several
disease conditions, including sepsis [23], acute respiratory distress syndrome [24], tuberculosis [25], and diabetes [26].
MIF has been shown to bind the transmembrane receptor CD74 and complex with CD44, with subsequent
signal transduction via extracellular signal-regulated kinases (ERK1/ERK2), which are subtypes of mitogenactivated protein kinases (MAPK) [27]. This leads to
several downstream effects that mediate the physiological effects of MIF. Particularly significant is the production of prostaglandin E2 (PGE2). Upregulation of
phospholipase A2 (PLA2) is likely important in both the
pro-inflammatory cascade and inhibition of glucocorticoid activity [28]. MIF also increases expression of TLR4,
which is involved in immune responses to pathogenic
bacteria as well as the pathogenesis of endotoxemia [29].
In addition, MIF promotes survival of pro-inflammatory
cells by inhibition of the tumor suppressor p53 [30].
MIF has been shown bind and inhibit JUN-activation
domain-binding protein 1 (Jab1), a coactivator of activator protein 1 (AP1), which is involved in cell growth.
MIF also acts as an enzyme in vitro, showing Ddopachrome tautomerase and thiol protein oxidoreductase activities [31,32].
There are multiple lines of research pointing to a role
for MIF in the pathobiology of depression. These findings have (i) identified MIF expression in the brain, particularly in areas significant to the behavioral symptoms
of depression; (ii) established the significance of the
hypothalamic-pituitary-adrenal (HPA) axis in depression,
with which MIF has an intricate relationship; (iii) shown
an interaction between MIF and both lifestyle and
pharmacological antidepressant treatments; (iv) determined a connection between MIF and neurogenesis, another important avenue of depression research; and (v)
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explored MIF as a biomarker in major depression and
other mood disorders. There is still much uncertainty
about MIF’s exact pathophysiologic role, and whether its
activity promotes or obstructs pathological processes in
depression. The goal of this review is to summarize
current research on the topic, highlight evidence for
MIF as a pro- or antidepressant, and address the potential for future developments in this area.
MIF in the central nervous system

Although MIF was originally identified as a product of
T-lymphocytes, it was later discovered to be ubiquitous,
with especially high expression rates in epithelia and
endocrine tissues [20]. Several studies have also highlighted
MIF expression in the central nervous system (CNS).
Immunostaining of bovine brain has established MIF
expression in the subependymal astrocytes, CA3/CA4
pyramidal cells of the hippocampus, and granule cells of
the dentate gyrus [33]. Similar techniques have been
used to localize MIF expression in rat brain to choroid
plexus epithelia, ventricular ependymal cells, and cerebral
astrocytes; the presence of MIF mRNA in astrocytes
and neurons has also been confirmed with in situ
hybridization [34]. An analysis of rat brain by Bacher
and colleagues revealed MIF expression in neurons of
the cortex, hypothalamus, hippocampus, cerebellum,
and pons [35]. Conboy et al. used immunohistochemistry
to establish MIF expression in astrocytes and the subgranular zone of the hippocampus [36]. Interestingly,
several of these areas contain proliferating or maturing
cell populations, which is an important consideration
for neurogenesis. There is significant regional association
with glucocorticoid activation.
MIF has also been isolated in human brain tissue, with
high levels of MIF mRNA expression in all regions [37].
Human neural MIF maintains high expression levels
throughout life (compared to other tissues, whose levels
decline with age), which has led some to propose a
maintenance role for MIF in isomerization of reactive
catecholamine metabolites to neuromelanin precursors
[38]. Neuromelanin has been shown to be neuroprotective in the pathobiology of Parkinson’s disease due to its
role as a scavenger and sink for toxic metabolites [39].
MIF has putative roles in several CNS inflammatory
conditions, including multiple sclerosis [40] and cerebral
ischemia-reperfusion injury [41], as well as being implicated in tumor growth in the CNS [19].
Extensive research has been done in identifying brain
areas significant in depression. Schmidt and colleagues
identified corticostriatal projection neurons as being essential for antidepressant response [42]. A 2008 review
of neuroimaging, lesioning, and postmortem analyses
posits a visceromotor network underlying the physiology
of emotion and mood, with dysfunction in this circuit
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leading to the symptoms of depression [43]. This network involves interplay between the medial prefrontal
cortex, amygdala, hippocampus, and various limbic
structures. It is noteworthy that this circuit includes the
hippocampus, one of the areas previously identified as
showing high MIF expression. This model has been applied to deep brain stimulation, an emerging approach
to treatment-resistant depression [44].
MIF and glucocorticoids

As mentioned above, MIF opposes the activity of glucocorticoids on the immune system. This activity of
glucocorticoids is well understood, and oral corticosteroids are in use by 0.5% of the general population. Glucocorticoids are produced endogenously as cortisol
and released by the adrenal glands upon stimulation by
adrenocorticotropic hormone (ACTH), secreted by corticotropic cells of the anterior pituitary; those cells release ACTH in response to stimulation by hypothalamic
corticotropin-releasing hormone (CRH). This process is
called the HPA axis. Corticosteroids bind cytosolic receptors that dimerize and translocate to the nucleus,
downregulating transcription of pro-inflammatory cytokines and decreasing production of prostaglandins
[21]. These effects are mediated by interactions with
NFkB [45], an important transcriptional regulator.
Specifically, glucocorticoids upregulate expression of
annexin 1 [46] and MAPK phosphatase 1 (MPK1) [47],
which both cause downregulation of PLA2. In addition
to being involved with the production of prostaglandins and leukotrienes from arachidonic acid, PLA2
also stimulates release of cytokines via Jun N-terminal
kinases (JNK) [48].
As discussed above, MIF causes upregulation of PLA2,
likely downstream of ERK1/2 signaling pathways [28]. It
may also affect NFkB via its interaction with Jab1, which
can lead to suppression of the inhibitory binding factor
of NFkB (IkB) [22]. MIF is expressed in cells at every
level of the HPA axis [49]. Its plasma levels follow a circadian rhythm that is comparable to that observed for
plasma cortisol [21], and it is released from pituitary
cells by CRH in a dose-dependent fashion [50]. Cortisol
has also been shown to induce secretion of MIF with a
bell-shaped dose response curve [51], in which high
levels suppress MIF production. This seems to indicate a
homeostatic balance between MIF and glucocorticoids,
with the dominant species determining whether to promote immune responses (in infection) or dampen them
(to protect from the harmful effects of inflammation).
It is well established that patients with MDD experience dysregulation of the HPA axis, manifesting as alterations in cortisol secretion and loss of suppression by
dexamethasone [52,53]. These abnormalities manifest in
40 to 60% of patients with MDD [54]. This HPA
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dysregulation is similar to the hormonal changes observed in Cushing’s disease, albeit to a lesser degree [55];
interestingly, Cushing’s patients experience a greater
incidence of mood disorders, which resolve upon
normalization of cortisol levels [56]. Although patients
with MDD do not experience Cushingoid symptoms per
se, strong associations have been found between the
hypercortisolism of depression and physical changes associated with Cushing’s disease, including hippocampal
atrophy, cognitive impairment, and abdominal obesity
[55]. These hormonal changes seem to be related to adrenal hyperresponsiveness to ACTH [54] as well as altered responses to glucocorticoids, especially at the
level of negative feedback in the pituitary [17].
The relationship between altered glucocorticoid signaling and depression has been reiterated in mouse models,
although there is still insufficient evidence to substantiate a true ‘glucocorticoid receptor theory of depression’
[57], especially since roughly half of MDD patients do
not manifest HPA abnormalities. However, HPA dysregulation may represent one pathway among many that
converge to produce the symptoms of depression. Significantly, stress and corticosteroids have also been
shown to inhibit hippocampal neurogenesis; this effect is
reversed by antidepressants [58]. MIF’s role in this
scheme has been investigated: Edwards et al. found that
MIF levels were 40% higher in healthy volunteers who
showed depressive symptoms on the Beck Depression
Inventory (BDI), and elevated MIF was associated with
decreased cortisol response to acute stress and lower
morning cortisol values [59].
MIF and antidepressant treatments

Antidepressant response is a commonly used paradigm
in depression research. Since the pathobiology and genetics of depression remain unknown, and many of its
symptoms are impossible to replicate in an animal
model, it has become necessary to design experimental
models based on reproducible responses to established
antidepressant treatments [60,61]. These models utilize
both classical treatments, such as selective serotonin reuptake inhibitors (SSRIs) and electroconvulsive therapy
(ECT), as well as new treatments like increased physical
activity and deep brain stimulation [62].
MIF has been tested against traditional antidepressant
treatments. An assay of motivated behavior has shown
an association between the ERK1/2 pathway and responses to tricyclic antidepressants [63]. Conboy and
colleagues determined that fluoxetine, a commonly administered SSRI [13], causes an increase in neurons immunoreactive for MIF. They also found that MIF
knockout (KO) mice and mice given the MIF inhibitor
[64] ISO-1 showed decreased neurogenesis after administration of fluoxetine. In addition, deletion of MIF
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resulted in increased depressive symptoms in the Porsolt
forced swim test for behavioral despair (FST) and impairments in hippocampal spatial learning and memory
in the Morris water maze. They concluded from these
results that MIF is significant in the neurogenic effects
of antidepressants [36].
Physical activity (PA) is emerging as an exciting new
avenue of therapy for depression. PA has relatively few
adverse effects, and can positively influence other
physiological and psychological disorders. PA has been
shown to be immunomodulatory, promoting expression
of certain cytokines and immune cells and reducing
others, as reviewed elsewhere [65]. PA also induces production of erythropoietin (EPO), a glycoprotein hormone involved in red blood cell hematopoiesis [66].
EPO and its receptor have recently been elaborated in
the CNS [67], and they have been shown to have neurotrophic and neuroprotective effects [68].
Moon et al. found that the antidepressant effects of exercise were partially mediated by MIF, which they concluded
functions as an antidepressant [69]. Using data from mRNA
microarrays, they determined that both voluntary exercise
and ECT induce MIF. Similar to the results from Conboy
et al. [36], MIF−/− mice showed increased depressive behavior and decreased antidepressant effects from exercise on
the FST. Intracerebroventricular (icv) MIF administration
had a direct antidepressant effect on the FST. They
also analyzed gene expression patterns for brain-derived
neurotrophic factor (BDNF), an important species in
neurogenesis [70], and tryptophan hydroxylase-2 (Tph2),
a rate-limiting enzyme in brain production of serotonin
[71]. Both were upregulated in exercise and icv administration of MIF. Induction of Tph2 by MIF was matched
with increased expression of serotonin in a recombinant
cell line. It was further determined that these effects are
all dependent on CD74 and ERK1/2, both established factors in MIF signal transduction [20,64].
MIF and neurogenesis

MIF is known to have a role in embryonic development
and cellular proliferation. As mentioned above, it promotes cell growth and inhibits apoptosis via inhibition
of p53, a tumor suppressor protein. Swant et al. established in fibroblasts that RhoA GTPase is an important
link between MIF and cyclin D1, which promotes cell
cycle progression by phosphorylation of Rb, another
tumor suppressor protein [72]. Inactivation of Rb leads
to disinhibition of E2F, which promotes synthesis of S
phase proteins and subsequent cellular proliferation
[73]. MIF directly stimulates activation of RhoA.
Ito and colleagues determined that MIF is an important factor in embryonic development of zebrafish, a
commonly used model for embryogenesis. Using wholemount in situ hybridization (WISH) they detected
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widespread MIF expression in embryonic structures, including eyes, tectum, branchial arches, and gut structures. Using antisense Morpholino-mediated knockdown
(MO), they determined that MIF MO fish displayed a reproducible phenotype of abnormal development in eyes
and cartilage structures, and, significantly, in brain structures such as the tectum and fourth ventricle [74]. Similar expression patterns have been observed in avian,
murine, and other mammalian models [75-77]. MIF has
also been shown to promote proliferation and survival of
neural stem progenitor cells in vitro [78].
It is notable that MIF expression in the brain is localized in regions of cellular proliferation. As discussed
above, MIF expression has been found in proliferating
cells of the subgranular zone of the hippocampus, and is
modulated by treatments affecting neurogenesis (chronic
stress, corticosteroids, and antidepressants). MIF deletion by genetics or inhibitors also attenuates both basal
and induced neurogenesis [36]. Similarly, Moon et al.
found that MIF induces the production of BDNF [69],
whose role in neurogenesis is well-established [70]. A
summary of results from significant animal studies of
MIF and depression can be found in Table 1.
MIF as a biomarker

With inflammation implicated in pathophysiology of depression, several groups have examined cytokines as depression biomarkers [79]. Rodent studies have indicated
that serum MIF increases in response to acute stress
[49,80]. Several groups have examined MIF levels in human serum in the context of depressive symptoms. A
study of male undergraduate students presented with a
public speaking task determined that subjects with mild
to moderate depression on the BDI demonstrated higher
baseline serum levels of MIF as well as increased lymphocytes [59,81]. Similar results have been reported in
pregnant women, where an association was determined
between depressive symptoms and increased MIF. Increased serum MIF was also observed after an immune
challenge in pregnant patients with depressive symptoms
as measured by the Center for Epidemiologic Studies
Depression Scale (CES-D) [82]. Interestingly, studies of
healthy patients with negative mood symptoms as measured by the Zung self-rating depression scale (SDS)
showed no significant association between serum MIF
and SDS mood scores [83]; associations were found with
IL-1β, a species known to be elevated in depression [84].
MIF has also been examined as a biomarker in the
context of clinical depression. In a drug trial examining
celecoxib add-on therapy to reboxetine (a norepinephrine reuptake inhibitor), MDD patients had an increased
serum MIF at baseline with no change during treatment
[85]. Similar results were found in an analysis of
leukocyte mRNA expression in serum from participants

Bloom and Al-Abed Journal of Neuroinflammation 2014, 11:11
http://www.jneuroinflammation.com/content/11/1/11

Page 5 of 9

Table 1 Animal studies of macrophage migration inhibitory factor (MIF) in the setting of depression or depressive
etiologies
Authors Model (n)

Intervention

Analysis

Results

Conboy Adult male Wistar rats (48)
et al. [36]

Chronic unpredictable stress,
chronic corticosterone

Immunohistochemistry for Ki-67,
MIF-IR cells in dentate gyrus

MIF co-localizes with proliferative
markers
MIF levels correlate with
neurogenesis

WT and MIF KO mice (16)

Fluoxetine (ip, od/14days),
ISO1 (od/14days)

Immunohistochemistry for PCNA,
DCX, BrdU, Ki-67, MIF-IR cells in
dentate gyrus

Loss of MIF results in decreased
basal and antidepressantstimulated neurogenesis

WT and MIF KO mice
(9, 16, 20, 8)

Acute stress exposure

ELISA for serum corticosterone,
MIF KO mice show no significant
Western blot for receptor expression difference from WT in levels of
serum glucocorticoids or receptor
expression

WT and MIF KO mice (52, 20)

None

FST, water maze, acoustic fear
conditioning

MIF KO mice show increased
behavioral despair
MIF KO mice show impaired
hippocampal spatial learning and
memory, intact amygdalar fear
conditioning

Moon
Male Sprague–Dawley rats
et al. [69] (13, 4)

Voluntary exercise (running
wheel), ECS (55 mA pulses,
100/s)

RT-PCR, Western blot,
immunohistochemistry for MIF
mRNA/protein

MIF mRNA is upregulated by
exercise and ECS

Neuro-2A and RBL-2H3 cells (3);
WT and MIF KO mice (12 to
16); male Sprague–Dawley rats
(8 to 12)

MIF (300 ng/mL), exercise/ECS
(see above), MIF (icv), CD74
siRNA, CT04 (5ug/mL), U0126
(10 uM)

RT-PCR for candidate genes (Bdnf,
Fgf2) and neurogenesis genes (Dcx,
Pax6), HPLC for 5HT, Western blot
for P-ERK1/2

MIF induces expression of BDNF
and Tph2, and also increases
intracellular concentrations of 5HT

WT and MIF KO mice (12 to
16); male Sprague–Dawley rats
(16 to 20)

Exercise (see above), MIF (icv)

FST

MIF KO mice show diminished
antidepressant effects of exercise

Effects on BDNF, Tph2, and 5HT
are CD74 and ERK1/2 dependent

Exogenous recombinant MIF has
antidepressant activity

ECS = electroconvulsive shock; FST = forced swim test; icv = intracerebroventricular injection; ip = intraperitoneal injection; IR = immunoreactive; KO = knockout;
od = once daily; WT = wild-type.

in the Genome-based Therapeutic Drugs for Depression
(GENDEP) project. In addition to observing increased
MIF in MDD patients compared to healthy controls, the
group also found that treatment responders had significantly higher levels of serum MIF than patients who
resisted treatment. MIF levels were shown to reduce
over time in this study, but this was not associated with
treatment response [86]. Results of human studies with
MIF and depression are summarized in Table 2.

Discussion
Despite significant evidence for MIF involvement in
the pathobiology of depression, some uncertainty remains about its exact role. MIF is an established species in the brain with suggested protective roles against
neurodegenerative disease [38]. Multiple groups have
identified a role for MIF in mediating antidepressant
activities, and have shown that loss of MIF results in
an antidepressant phenotype; there is even evidence
that MIF has direct antidepressant effects. These studies have linked MIF to monoamine production and
neurogenesis, both implicated in the pathobiology of

depression [36,69]. Conversely, increased serum MIF
has been identified in both patients with major depression and healthy subjects with depressive symptoms
[81,82,85,86], although these studies have shown
mixed results [83]. At least one study has associated
these changes with the HPA axis, which has also been
implicated in depression [59]. See Figure 1 for a summary of putative roles for MIF in depression.
It seems counterintuitive to assert that MIF is both an
antidepressant and a biomarker of depression. However,
it is important to realize that the Conboy and Moon
studies were working with MIF native to the brain, while
the biomarker studies were analyzing MIF levels in peripheral blood. MIF does not cross the blood brain barrier [87,88], and differential expression in the two areas
may explain the differing observations. MIF levels in
plasma may be incidental to the mechanisms of depression or may arise as a consequence of a different but
related process. It is also possible that the two results
are not mutually exclusive, and increased MIF in depressed individuals is a physiological adaptation to the
pathobiological changes of depression. It is notable in
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Table 2 Controlled studies of macrophage migration inhibitory factor (MIF) in major depressive disorder (MDD) or
depressive mood
Authors

Subjects

Depression Intervention
measures (duration)

Hawkley
et al. [81]

75 subjects

BDI

Analysis (t)

Pertinent results

Public speaking stress Serum MIF (0, 15 minutes)
task (once)

MIF levels are increased in subjects showing mild to
moderate depression (BDI)
MIF levels are unaffected by the public speaking
stress task

Edwards
et al. [59]

126 healthy
subjects

BDI
UCLA-R

Public speaking stress ELISA for serum MIF (0, 3, 15, MIF levels are increased at baseline in subjects
task (once)
45 minutes)
showing high depressive symptoms (BDI)
MIF levels do not change over the time course
measured

Christian
et al. [82]

22 pregnant
subjects

CES-D

Vaccination for
ELISA for serum MIF (0, 1
influenza virus (once) weeks)

Pregnant women with depressive symptoms (CES-D)
show increased MIF levels at 1 week

Katsuura
et al. [83]

209 healthy
subjects

Zung-SDS

None

Multiplex suspension array
for serum levels of multiple
immune mediators (0)

MIF levels are not significantly associated with
depressive symptoms (SDS)

Musil
et al. [85]

32 MDD
patients, 20
healthy
controls

DSM-IV

Treatment with
reboxetine and addon celecoxib
(5weeks)

ELISA for serum MIF, TGFB,
and sCD14 (0, 3, 5 weeks)

MIF levels are increased at baseline in MDD patients

HRSD

MIF levels are unchanged during reboxetine
treatment
Celecoxib reduces HamD scores but does not affect
MIF levels

Cattaneo
et al. [86]

74 MDD
patients, 34
healthy
controls

DSM-IV
MADRS
HRSD

Treatment with
escitalopram or
nortryptiline
(8 weeks)

qPCR for serum leukocyte
MIF mRNA levels are increased at baseline in
mRNA levels of several
treatment-responsive MDD patients; MIF mRNA levels
candidate genes (0, 8 weeks) decrease during treatment, but with no correlation to
treatment response

BDI
All studies collected serum from subjects at the times indicated (0 = baseline) for measurements of peripheral MIF levels. BDI = Beck Depression Inventory;
CES-D = Center for Epidemiologic Studies Depression Scale; DSM-IV = Diagnostics and Statistics Manual of Mental Disorders, 4th edition; HRSD = Hamilton Depression
Scale 17-item version; MADRS = Montgomery-Asberg Depression Rating Scale; SDS = Self-Rating Depression Scale; UCLA-R = Revised UCLA Loneliness Scale.

this regard that increased MIF in depressed patients has
been found to correlate with treatment response [86].
MIF underlies the pathophysiology of several disease
conditions, and MIF inhibition is well characterized and
widely used in research [64]. Anti-MIF antibodies are
currently being investigated in Phase I clinical trials [89].
It seems inevitable that some form of MIF inhibitors will
soon become available at the clinical level. When this

BDNF

MIF

neurogenesis
GCs

Tph2

5HT

NM
neuroprotection
antidepressants
exercise

Figure 1 Putative roles for macrophage migration inhibitory
factor (MIF) in depression. GCs = glucocorticoids; NM = neuromelanin.
(Single column fitting figure; color for Web only).

occurs, MIF’s role in depression - whatever it may be will be highly relevant. If MIF is found to promote depression, then MIF inhibitors could be investigated as
antidepressants; ISO-1, the most tested MIF inhibitor,
has already been shown to cross the blood brain barrier
[36]. If MIF acts as an antidepressant, then anti-MIF
therapeutics can be engineered not to cross the blood
brain barrier, bypassing depression as a possible offtarget effect.

Conclusion
There are clear gaps in the research concerning MIF and
depression. Future studies should work to elucidate the
relationship between central and peripheral MIF in depression, if any exists. Further work should also be done
to clarify MIF’s role as a pro- or antidepressant and its
place in the pathobiology of depression. It may be useful
to further analyze relationships with factors in and out
of the monoamine and neurogenic pathways that have
been shown to impact depression. Imaging studies have
emerged as an important modality in neuropsychiatric
disorders, including depression [90,91]; it may prove interesting to test how alterations in MIF expression affect
the presentation of the disease on imaging studies. One
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advantage in these projects will be the fact that MIF is a
well-studied molecule, with both established inhibitors
and KO strains in rodent models.
Although there is much to be done, it seems beyond
doubt that MIF has great potential in studies of the
mechanisms of major depression. In addition to interacting with known elements involved in the physiological
changes of depression, it is also active in the brain and
can be shown to have independent effects on the depression phenotype. In addition to expanding our knowledge
about this still-enigmatic disease, such studies can also
inform current drug development efforts with anti-MIF
therapy, as well as possibly provide the stagnant field of
antidepressant treatment with a valuable new target in
modifying the course of this disease.
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